TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
|Articles|August 14, 2013
Chronic GERD: What’s Your Next Step?
GERD of long-standing duration may require on-demand PPI dosing-and evaluation for esophageal damage.
Advertisement
A 58-year-old obese man presents to your clinic for follow-up of GERD. He has had reflux symptoms, characterized by heartburn and regurgitation, for more than 20 years. His reflux worsens when he is supine. His symptoms are generally well-controlled with once-daily PPI dosing, but he occasionally requires an on-demand second dose. Which of the following strategies would you recommend?
A. Refer for upper endoscopy to screen for Barrett esophagus
B. Refer for barium swallow to document GERD
C. Confirm presence of GERD with 24-hour pH study
D. Continue PPI therapy indefinitely and refer only if symptoms change
Advertisement
Related to this article
Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and promise for primary care triage to endoscopy.
Post hoc LUCENT-2 and VIVID-1 analyses show more mirikizumab-treated patients reached steroid-free composite remission in UC and Crohn disease at 1 year.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
4 FDA Decisions for Primary Care to Know from October 2026
2
When Night Sweats Signal Something Other Than Menopause
3
Mediterranean Diet Linked to Lower Odds of Adult Acne in New Study
4
Abbott's Amulet 360 Linked to Low Stroke Risk at 1 Year in Late-Breaking Research
5